https://www.selleckchem.com/pr....oducts/act001-dmamcl
Triple combination therapy against PI3KCDK4/6ER prevented and/or delayed the onset of resistance in treatment-naive ER+/HER2- breast cancer models. These data support the clinical investigation of p110α-selective inhibitors of PI3K, such as alpelisib, in patients with ER+/HER2- breast cancer who have progressed on CDK4/6ER-based therapies. Our data also support the investigation of PI3KCDK4/6ER triple combination therapy to prevent the onset of resistance to the combination of endocrine therapy plus CDK4/6 inhibition. These data s
Giống
Bình luận
Đăng lại
